Cocrystal Pharma, Inc.

Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.

COCP | US

Overview

Corporate Details

ISIN(s):: US19188J4094
LEI:
Country:: United States of America
Address:: 19805 N. CREEK PARKWAY, 98011 BOTHELL
Website:: https://www.cocrystalpharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. The company utilizes its proprietary structure-based drug design technologies and Nobel Prize-winning expertise to create antiviral drugs that target the viral replication process. Its development pipeline includes candidates for the treatment of influenza, coronaviruses (including SARS-CoV-2), norovirus, and hepatitis C. Key programs in its portfolio are at various stages of clinical development, including a Phase 2 trial for an influenza A inhibitor (CC-42344) and a Phase 1 trial for a pan-viral protease inhibitor (CDI-988) targeting norovirus and coronaviruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cocrystal Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cocrystal Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Cocrystal Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
	LAVA Therapeutics NV Develops bispecific gamma delta T cell engagers for solid and hematologic cancers.	United States of America	LVTX
	Lavipharm S.A. Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.	Greece	LAVI
	LB PHARMACEUTICALS INC Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.	United States of America	LBRX
	Legend Biotech Corp Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.	United States of America	LEGN
	LENZ Therapeutics, Inc. Develops a prescription eye drop for presbyopia, the age-related loss of near vision.	United States of America	LENZ
	Lexaria Bioscience Corp. Biotech firm with patented technology improving oral drug delivery and absorption.	United States of America	LEXX
	Lexeo Therapeutics, Inc. Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.	United States of America	LXEO
	LEXICON PHARMACEUTICALS, INC. Develops gene-based drugs for chronic diseases, including treatments for heart failure.	United States of America	LXRX
$LIFECORE BIOMEDICAL, INC. \DE\ Logo$	LIFECORE BIOMEDICAL, INC. \DE\ A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).	United States of America	LFCR
	Liminatus Pharma, Inc. Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.	United States of America	LIMN